Electrochemotherapy (ECT) in animal models of pancreatic cancer
| Reference | Animal models | Cell lines | Methods | Drugs | Effects |
|---|---|---|---|---|---|
| Nanda et al., 199812 | Nude mice | Pan-4JCK | ECT | Bleomycin | Tumour regression after 89 days |
| Carboplatin | |||||
| Mitomicin C | |||||
| Dev et al., 200037 | Nude mice | BxPc3 | ECT | Cisplatin | Tumour regression after 28 days |
| Doxorubicin | |||||
| Fluruoracil | |||||
| Jaroszeski et al., 199913 | Golden | PC-1 | ECT | Bleomycin | 100% complete response rate in subcutaneous tumours, 25% response rate in orthotopic tumours |
| Syrian | |||||
| hamster |
Electrochemotherapy treatment in pancreatic cancer cell lines
| Reference | Cell lines | Drugs | IC50 (P value) | Methods | EP parameters |
|---|---|---|---|---|---|
| Girelli et al., 201517 | PANC1 | Bleomycin | < 0.0001 | MTS assay | 8 pulses, 100 μs of duration, 5 Hz |
| MiaPaCa2 | Cisplatin | ≤ 0.0001 | FACS | ||
| Sundararajan, 201426 | PANC1 | Gemcitabine | < 0.0001 | MTS assay | high intensity, low duration (microseconds) pulses; low intensity and long duration pulses (milliseconds). |
| PANC28 | ≤ 0.0001 |
Clinical studies on irreversible electroporation (IRE) in pancreatic cancer
| Reference | No. of patients | Stage of pancreatic cancer | Results |
|---|---|---|---|
| Bagla et al., 201254 | 78 | Stage III | No residual disease and a decreasing cancer antigen 19-9 level. |
| Mansson et al., 201455 | 5 | No serious treatment-related adverse events were observed. | |
| Paiella et al., 201556 | 10 | Stage III | Overall survival of 7.5 months |
| Martin et al, 201357 | 54 | Stage III | Improvement in local progression-free survival (14 vs. 6 months, p = 0.01), distant progression-free survival (15 vs. 9 months, p = 0.02), and overall survival (20 vs. 13 months, p = 0.03). |
| Martin et al, 201458 | 48 | Stage III | No significant vascular complications were seen, and of the high-grade complications, bleeding (2), biliary complications (3) and DVT/PE (3) were the most common. |